Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Guillain-Barré Syndrome

Neurological & Neuromuscular

Guillain-Barré Syndrome (GBS) Clinical Trials and Treatments

Also called GBS, Landry's ascending paralysis, acute inflammatory demyelinating polyneuropathy, AIDP

Guillain-Barré syndrome is an acute autoimmune polyneuropathy in which the immune system mistakenly attacks components of the peripheral nervous system. In the most common form (acute inflammatory demyelinating polyneuropathy or AIDP), antibodies target the myelin sheath surrounding peripheral nerves, disrupting nerve signal transmission and causing rapidly progressive weakness. The condition typically begins with tingling and weakness in the feet and legs that ascends over hours to days, potentially involving the arms, trunk, cranial nerves, and respiratory muscles.

In plain words, Guillain-Barré syndrome is a rare condition where the immune system attacks the nerves outside the brain and spinal cord. Weakness and tingling often start in the legs and can spread to the arms and face.

Get an email when new Guillain-Barré Syndrome trials open or the FDA decides. Get alerts

Guillain-Barré Syndrome

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 13 studies with no phase, like observational studies, and 1 combined-phase study, such as Phase 1/2, counted at the later phase.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Guillain-Barré Syndrome yet.

Guillain-Barré Syndrome has no FDA-approved medicines, 17 open or active clinical trials (9 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Guillain-Barré Syndrome

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Guillain-Barré Syndrome

GBS is usually triggered by a preceding infection, most commonly Campylobacter jejuni gastroenteritis, but also by respiratory viruses, cytomegalovirus, Epstein-Barr virus, and Zika virus. The immune response generated against the pathogen cross-reacts with gangliosides or other components on peripheral nerve membranes through molecular mimicry.

Keep reading about Guillain-Barré Syndrome

Treatment with intravenous immunoglobulin (IVIG) or plasma exchange can shorten the course and severity. About 80% of patients can walk on their own again within 6 months, though full recovery can take months to years and many keep some weakness, pain or fatigue. Approximately 5% of cases are fatal, usually from respiratory failure or cardiac complications.

What are the symptoms of Guillain-Barré Syndrome?

These are common symptoms of Guillain-Barré Syndrome, and how strong they are varies from person to person.

  • Tingling or weakness starting in the feet and legs, spreading upward
  • Difficulty walking, climbing stairs, or using facial muscles
  • Muscle weakness affecting both sides of the body
  • Chest weakness that may affect breathing
  • Deep muscle pain, especially in back and legs
  • Changes in blood pressure or heart rate

Who gets Guillain-Barré Syndrome?

Can occur at any age but is slightly more common in adults over 50 and in males. Often develops days or weeks after a respiratory or gastrointestinal infection, particularly Campylobacter jejuni. Rare cases have been associated with certain vaccinations or surgical procedures.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Which new Guillain-Barré Syndrome medicines are in trials?

Investigational medicines Trial Friend tracks for Guillain-Barré Syndrome, with trial results, safety findings and where each one stands.

How to get help paying for Guillain-Barré Syndrome treatment

Charity funds and drugmaker programs for Guillain-Barré Syndrome, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · NORD RareCare
    Guillain-Barre Emergency Relief Assistance fund
    Open

    Pays for: Emergency relief.

    The foundation says: “Accepting Applications”
Status as each foundation showed it on November 20, 2026.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

How Guillain-Barré Syndrome is diagnosed

A post-infectious immune attack on peripheral nerves; almost all cases are sporadic and no genetic test has a role.

Trusted Guillain-Barré Syndrome resources

Reputable organizations and medical references for learning more about Guillain-Barré Syndrome, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Guillain-Barré Syndrome

Use this Guillain-Barré Syndrome clinical trial finder to see the 9 studies recruiting patients and 8 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 7 test a treatment and 10 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

17 active trials worldwide
Filter:
Sort:
Not yet recruitingTreatment trialRecently updatedNCT07935382

PNF Combined With Core Strengthening Exercise in Sub-acute Guillian Barre Syndrome Patients (PNF-CORE-GBS)

Intervention: Proprioceptive neuromuscular facilitation, core strengthening exercise, conventional physiotherapy

Sponsor: University of Lahore

A total of 32 participants aged 18-45 years with clinically diagnosed sub-acute GBS will be allocated into two groups. The intervention group will receive PNF techniques combined with core strengthening exercises, while the control group will receive conventional physiotherapy. T...

Ages 18 Years to 45 Years1 location
Expected to start Nov 2026Updated 4 days agoEst. Apr 2027 (~5 months)
RecruitingObservational study, no treatment givenRecently updatedNCT07935733

Blood Biomarkers for Prognostic Stratification in Guillain-Barré Syndrome

Intervention: Blood Biomarker Panel Assessment (EGR1, EGR2, GBP1, miR-29c, and Piccolo)

Sponsor: Anahuac University

Guillain-Barré syndrome (GBS) is an acute immune-mediated peripheral neuropathy characterized by substantial variability in clinical severity, functional recovery, and pain outcomes. The lack of validated and accessible prognostic biomarkers limits early risk stratification and individualized rehabilitation strategies.

Ages 16 Years+2 locations
Expected to start Dec 2027Updated 1 week agoEst. Dec 2027 (~1 year)
RecruitingTreatment trialRecently updatedNCT06822231

High-Tech Rehabilitation Pathway for Acute Adult Neuromuscular Diseases - Fit4MedRob-Acute MND Project

Intervention: High-tech rehabilitative treatment, Rehabilitation

Sponsor: Istituti Clinici Scientifici Maugeri SpA

The goal of this study is determine if a high-tech rehabilitation circuit is more effective than usual rehabilitation methods in improving functional outcome, particularly balance control, for patients with acute neuromuscolar diseases. The main question it aims to answer is:

Ages 18 Years to 80 Years
Started May 2025Updated 2 weeks agoEst. May 2027 (~6 months)
Not yet recruitingTreatment trialPhase 2Recently updatedNCT07821762

A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome

Intervention: Empasiprubart IV, Empasiprubart Placebo IV, Intravenous immunoglobulin (IVIg)

Sponsor: argenx

The main purpose of this study is to learn whether empasiprubart, when given in addition to intravenous immunoglobulin (IVIg), helps adults with Guillain-Barré syndrome (GBS) recover and whether it is safe. About 63 participants will be assigned by chance to receive either empasi...

Ages 18 Years+
Expected to start Dec 2026Updated 3 weeks agoEst. Jan 2028 (~1y 2m)
RecruitingTreatment trialPhase 3Recently updatedNCT07020819

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

Intervention: Tanruprubart

Sponsor: Annexon, Inc.

The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.

Ages 8 Years to 85 Years
Started Sep 2025Updated 3 weeks agoEst. May 2027 (~6 months)
Find Guillain-Barré Syndrome trials near you, ranked by distance →
Active trial locations21 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+13 more

Trial Pipeline

Mar 2021 to Apr 2030
2022
2024
2026
2028
2030
now
Phase 2
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Guillain-Barré Syndrome trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Guillain-Barré Syndrome foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Guillain-Barré Syndrome patient communities

Facebook groups, Reddit communities and YouTube channels where Guillain-Barré Syndrome patients, caregivers and advocacy groups talk.

Companies developing Guillain-Barré Syndrome treatments

Drugmakers that list Guillain-Barré Syndrome in their rare disease portfolio, 5 in all.

Questions people ask about Guillain-Barré Syndrome